Filing Details

Accession Number:
0001562180-15-000524
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-06-24 16:27:02
Reporting Period:
2015-06-22
Filing Date:
2015-06-24
Accepted Time:
2015-06-24 16:27:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1404281 Tokai Pharmaceuticals Inc TKAI Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1618251 S. John Mcbride C/O Tokai Pharmaceuticals, Inc.
255 State Street, 6Th Floor
Boston MA 02109
Chief Operating Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-06-22 2,000 $4.19 2,000 No 4 M Direct
Common Stock Disposition 2015-06-22 2,000 $14.02 0 No 4 S Direct
Common Stock Acquisiton 2015-06-23 6,700 $4.19 6,700 No 4 M Direct
Common Stock Disposition 2015-06-23 6,700 $14.00 0 No 4 S Direct
Common Stock Acquisiton 2015-06-24 300 $4.19 300 No 4 M Direct
Common Stock Disposition 2015-06-24 300 $14.20 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2015-06-22 2,000 $0.00 2,000 $4.19
Common Stock Stock Option (right to buy) Disposition 2015-06-23 6,700 $0.00 6,700 $4.19
Common Stock Stock Option (right to buy) Disposition 2015-06-24 300 $0.00 300 $4.19
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
207,178 2024-02-25 No 4 M Direct
200,478 2024-02-25 No 4 M Direct
200,178 2024-02-25 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. This option vested with respect to 12.5% of the shares underlying the option on April 1, 2014 and vests with respect to an additional 2.0833% on the first day of each month thereafter through October 1, 2017.